10x Genomics, Inc. (TXG) saw its stock price surge 6.34% in after-hours trading on Thursday, following the release of its fourth quarter and full year 2025 financial results.

The significant after-hours gain appears driven by the company reporting better-than-expected quarterly performance. 10x Genomics posted a Q4 2025 loss per share of $0.13, which beat the analyst consensus estimate of a $0.20 loss. Quarterly revenue reached $166 million, also exceeding estimates of approximately $159 million. Furthermore, the company's net loss for the quarter narrowed substantially to $16.3 million from $49.0 million in the prior year.

Adding to the positive sentiment, the company provided its revenue outlook for the full year 2026, forecasting between $600 million and $625 million, which aligns with the consensus estimate. Other encouraging details from the report included an improved gross margin of 68% and a strengthened cash position, ending the year with $523.4 million in cash and equivalents.